Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
69.75 CHF | -0.21% | +9.45% | +36.54% |
Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
Mar. 20 | Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025 | CI |
Business Summary
Number of employees: 319
Sales per Business
CHF in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Own Products
52.0
%
| 43 | 60.6 % | 53 | 52.0 % | +25.05% |
Licence Fees, Up-front Fees and Milestones
23.8
%
| 6 | 8.5 % | 24 | 23.8 % | +310.51% |
Generic Products, Specialty Drugs and Related Services
12.9
%
| 14 | 19.4 % | 13 | 12.9 % | -3.41% |
Royalties
9.7
%
| 6 | 8.6 % | 10 | 9.7 % | +63.17% |
Other
1.6
%
| 2 | 2.9 % | 2 | 1.6 % | -17.40% |
Sales per region
CHF in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Italy
100.0
%
| 70 | 100.0 % | 102 | 100.0 % | +45.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 05-12-31 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 05-05-31 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 11-08-31 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 00-12-31 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 22-01-09 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 21-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 21-05-27 |
Founder | 69 | 96-12-31 | |
Director/Board Member | 64 | 05-12-31 | |
Director/Board Member | 69 | 12-03-31 | |
Director/Board Member | 65 | 16-02-29 | |
Chief Executive Officer | 61 | 05-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,543,522 | 7,842,715 ( 44.70 %) | 1,490,681 ( 8.497 %) | 44.70 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,283,390 | 7.32% | 96,048,381 $ | |
REDHILL BIOPHARMA LTD. 0.58% | 69,000,010 | 0.58% | 4,250,401 $ |
Company contact information
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comGroup companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.54% | 1.24B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.43% | 210B | |
+1.17% | 210B | |
-6.56% | 201B | |
-3.51% | 157B |
- Stock
- Equities
- Stock Cosmo Pharmaceuticals N.V. - Swiss Exchange
- Company Cosmo Pharmaceuticals N.V.